Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Santoni-Rugiu

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Thorax|March 28, 2024
To progress or not to progress: new insights into the evolution of pleuropulmonary blastomas come from studying lung cysts in adolescents and adults with <i>DICER1</i>-related tumour predispositionEric Santoni-Rugiu
European Journal of Cancer (Oxford, England : 1990)|April 17, 2010
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trialAdam Vilmar, Eric Santoni-Rugiu, Jens Benn Sørensen
Histopathology|March 8, 2012
The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomasZarah Glad Zimling, Anne Jørgensen, Eric Santoni-Rugiu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLCEdyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Histopathology|November 26, 2013
Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancerJan N Jakobsen, Eric Santoni-Rugiu, Jens B Sørensen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2011
Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trialAdam Christian Vilmar, Eric Santoni-Rugiu, Jens Benn Sørensen
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2023
Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Translational Lung Cancer Research|March 21, 2025
Alectinib impressively enters the adjuvant setting for early-stage <i>ALK</i>-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the mostEric Santoni-Rugiu, Jens Benn Sørensen, Edyta Maria Urbanska
Cancer Chemotherapy and Pharmacology|November 14, 2013
Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patientsJan Nyrop Jakobsen, Eric Santoni-Rugiu, Jens Benn Sørensen
Cancer Chemotherapy and Pharmacology|December 12, 2013
Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancerJan Nyrop Jakobsen, Eric Santoni-Rugiu, Jens Benn Sørensen
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Thorax|March 28, 2024
To progress or not to progress: new insights into the evolution of pleuropulmonary blastomas come from studying lung cysts in adolescents and adults with <i>DICER1</i>-related tumour predispositionEric Santoni-Rugiu
European Journal of Cancer (Oxford, England : 1990)|April 17, 2010
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trialAdam Vilmar, Eric Santoni-Rugiu, Jens Benn Sørensen
Histopathology|March 8, 2012
The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomasZarah Glad Zimling, Anne Jørgensen, Eric Santoni-Rugiu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Treatment Algorithm for Advanced ALK-Rearranged NSCLCEdyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Histopathology|November 26, 2013
Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancerJan N Jakobsen, Eric Santoni-Rugiu, Jens B Sørensen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2011
Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trialAdam Christian Vilmar, Eric Santoni-Rugiu, Jens Benn Sørensen
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2023
Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?Edyta Maria Urbanska, Jens Benn Sørensen, Eric Santoni-Rugiu
Translational Lung Cancer Research|March 21, 2025
Alectinib impressively enters the adjuvant setting for early-stage <i>ALK</i>-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the mostEric Santoni-Rugiu, Jens Benn Sørensen, Edyta Maria Urbanska
Cancer Chemotherapy and Pharmacology|November 14, 2013
Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patientsJan Nyrop Jakobsen, Eric Santoni-Rugiu, Jens Benn Sørensen
Cancer Chemotherapy and Pharmacology|December 12, 2013
Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancerJan Nyrop Jakobsen, Eric Santoni-Rugiu, Jens Benn Sørensen
Pageof 10